00:03 , Aug 24, 2017 |  BC Extra  |  Preclinical News

Inhibiting PP2A reduces MECP2 in neuropsychiatric model

In a paper published in Science Translational Medicine, researchers showed that inhibiting protein phosphatase 2 (PP2A; PPP2CA) reduced levels of methyl CpG binding protein 2 (MECP2; RTT), suggesting that modulating PP2A could treat neuropsychiatric conditions,...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Homeodomain interacting protein kinase 2 (HIPK2); TAR DNA binding protein 43 (TDP-43; TARDBP)

Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) In vitro and mouse studies suggest inhibiting HIPK2 could help treat ALS. In HEK cells and rat spinal motor neurons expressing a human ALS-associated TDP-43 mutation, an HIPK2 inhibitor tool compound...
07:00 , Mar 22, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Homeodomain interacting protein kinase 2 (HIPK2) Patient tissue and mouse studies suggest inhibiting HIPK2...